Main Article Content
Background: Platelet aphaeresis is an essential procedure, which meets the demand of single donor platelets (SDP) effectively. The procedure is well tolerated by donors with fewer side effects. Adverse events in Platelet aphaeresis have been reported from as low as 0.32 to 6.81%.
Aims and Objectives: The aim of present study is to ascertain adverse events observed in a large cohort of platelet aphaeresis procedures and determining management strategies to resolve them.
Materials and Methods: This is a retrospective cross-sectional study, from January 2012 to May 2019 in Blood Bank, Department of Pathology, in a tertiary care centre in Central India. Donors for Platelet aphaeresis were selected based on the standard criteria of National Aids Control Organization (NACO) guidelines 2017 and Platelet aphaeresis protocol. Leukoreduced SDP were collected by Haemonetics® MCS +, having Leukoreduction bag system. Adverse events encountered were noted and categorized.
Results: A total number of 1600 Plateletpheresis procedures were conducted to prepare SDP and transfused to 1054 patients. A total of 24 out of 1600 plateletaphaeresis procedures reported adverse events (1.5%). Donor related adverse events were 16 (66.6%), Kit related 4 (16.66%) procedure related were 4 (16.66%). Three out of 24 procedures were terminated prematurely, 1 due to severe hypocalcaemia (ACD effect) in donor and 2 due to bowl leakage.
Conclusion: Platelet aphaeresis is a safe procedure for donors if done expertly while exercising caution. Adverse events reported are minimal and manageable.
Estcourt L, Stanworth S, Doree C, Hopewell S, Murphy MF, Tinmouth A, et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev. 2012;5.
Despotis GJ, Goodnough LT, Dynis M, et al. Adverse events in platelet apheresis donors: A multivariate analysis in a hospitalbased program. Vox Sang. 1999;77:24–32.
Winters JL. Complications of donor aphaeresis. J Clin Apher. 2006;21:132–14.
Mc Leod BC, Price TH, Owen H, et al. Frequency of immediate adverse effects associated with aphaeresis donation. Transfusion. 1998;38:938–943.
NACO. Standards for Blood Banks & Blood Transfusion Services. National AIDS Control Organization Ministry of Health and Family Welfare Government of India New Delhi; 2007.
Available:http://naco.gov.in/blood-transfusion services- publications.
Khajuria K, Sawhney V, Sharma R, Gupta S. Adverse donor reaction during and after plateletpheresis in a tertiary care centre. Int J Res Med Sci. 2017;5:1221-3.
Dogra K, Fulzele P, Rout D, Chaurasia R, Coshic P, Chatterjee K. Adverse events during apheresis procedures: Audit at a tertiary hospital. Indian J Hematol Blood Transfus. 2017;33(1):106–108.
Bassi R, Thakur K, Bhardwaj K. Plateletpheresis adverse events in relation to donor and Plateletpheresis session profile. Iraqi J of Hematol. 2017; 6(2):41.
Crookston KP, Novak DJ. Physiology of apheresis. In: Mcleod BC, Szczepiorkowski ZM, Weinstein R, Winters JL, editors. Apheresis: Principles and practice 3rd ed., Ch. 3. Bethesda, Maryland: AABB Press. 2010;45‑65.
Philip J, Sarkar RS, Pathak A. Adverse events associated with apheresis procedures: Incidence and relative frequency. Asian J Transfus Sci. 2013;7:37‑41.
Bolan CD, Greer SE, Cecco SA, Oblitas JM, Rehak NN, Leitman SF. Comprehensive analysis of citrate effects during Plateletpheresis in normal donors. Transfusion. 2001;41:1165‑71.